🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 114 of 857 · Phase 3 first, then by program name

  1. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  2. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  3. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  4. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  5. NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  6. NBI-34060

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  7. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  8. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    6 trials

  9. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  10. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  11. NE-58095 IR

    Takeda

    Involutional Osteoporosis

    phase 3 small molecule completed

    1 trial

  12. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  13. NFC-1

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  14. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  15. NICOPASS 1,5 mg SANS SUCRE MENTHE FRAICHEUR, pastille édulcorée à l'aspartam et à l’acésulfame potassique, V0018 Placebo

    Pierre Fabre Medicament

    Cessation of smoking

    phase 3 small molecule active

    1 trial

  16. NICOTINAMIDE, cellulose microcristalline

    ISTA Pharma Limited

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  17. NIFEDIPINE, Placebo of Nifedipine

    Pari Pharma GmbH

    obstetric_pathological delivery

    phase 3 small molecule active

    1 trial

  18. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  19. NIO752, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Novartis Pharmaceuticals

    Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

    phase 3 small molecule active

    1 trial

  20. NIRMATRELVIR, NIRMATRELVIR, Ritonavir, nirmatrelvir / ritonavir

    Pfizer Australia Pty Ltd

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  21. NIS793

    Novartis Pharmaceuticals

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule completed

    1 trial

  22. NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL

    Amgen

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  23. NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. NKTR-102

    Nektar Therapeutics UK Limited

    Metastasis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources